WO1996016163A3 - Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung - Google Patents

Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung Download PDF

Info

Publication number
WO1996016163A3
WO1996016163A3 PCT/DE1995/001699 DE9501699W WO9616163A3 WO 1996016163 A3 WO1996016163 A3 WO 1996016163A3 DE 9501699 W DE9501699 W DE 9501699W WO 9616163 A3 WO9616163 A3 WO 9616163A3
Authority
WO
WIPO (PCT)
Prior art keywords
embryonal
gene
cardiac muscle
muscle cells
optionally
Prior art date
Application number
PCT/DE1995/001699
Other languages
English (en)
French (fr)
Other versions
WO1996016163A2 (de
Inventor
Wolfgang-Michael Franz
Anna M Wobus
Original Assignee
Inst Pflanzengenetik & Kultur
Wolfgang-Michael Franz
Anna M Wobus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pflanzengenetik & Kultur, Wolfgang-Michael Franz, Anna M Wobus filed Critical Inst Pflanzengenetik & Kultur
Priority to US08/849,706 priority Critical patent/US5928943A/en
Priority to EP95940117A priority patent/EP0787182A2/de
Publication of WO1996016163A2 publication Critical patent/WO1996016163A2/de
Publication of WO1996016163A3 publication Critical patent/WO1996016163A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

Die Erfindung betrifft embryonale (kardiomyozytäre und kardiomyoblastäre) Herzmuskelzellen, ihre Herstellung und ihre Verwendung, insbesondere zur zellvermittelten Gentransplantation. Anwendungsgebiete der Erfindung sind die Medizin und die Gentechnik. Die embryonalen Herzmuskelzellen gemäß der Erfindung enthalten zwei Genkonstrukte aus a) regulatorischer, 2,1 kb langer DNA-Sequenz des ventrikelspezifischen Myosin-Leicht-Kette-2 (MLC-2v) Promotors, dem selektionierbaren Markergen β-Galaktosidase in Fusion mit dem Reportergen Neomycin und aus b) regulatorischer DNA-Sequenz des Herpes-simplex-Virus-Thymidinkinase-Promotors und den selektionierbaren Markergen Hygromycin, sowie ggf. immortalisierende Gene und/oder ggf. durch homologe Rekombination inaktivierte Gene und/oder ggf. ein oder mehrere therapeutische Gene. Sie können vorteilhaft zur zellvermittelten Gentransplantation, insbesondere zum Aufbau gesunden Gewebes und zur Unterstüzung kontraktiler Funktionen, zur Untersuchung von Substanzen, insbesondere für pharmakologische Untersuchungen und für den Transfer therapeutischer Gene in das Myokard eingesetzt werden.
PCT/DE1995/001699 1994-11-22 1995-11-21 Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung WO1996016163A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/849,706 US5928943A (en) 1994-11-22 1995-11-21 Embryonal cardiac muscle cells, their preparation and their use
EP95940117A EP0787182A2 (de) 1994-11-22 1995-11-21 Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4441327.0 1994-11-22
DE4441327A DE4441327C1 (de) 1994-11-22 1994-11-22 Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung

Publications (2)

Publication Number Publication Date
WO1996016163A2 WO1996016163A2 (de) 1996-05-30
WO1996016163A3 true WO1996016163A3 (de) 1996-07-18

Family

ID=6533720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1995/001699 WO1996016163A2 (de) 1994-11-22 1995-11-21 Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung

Country Status (4)

Country Link
US (1) US5928943A (de)
EP (1) EP0787182A2 (de)
DE (1) DE4441327C1 (de)
WO (1) WO1996016163A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
JP2000500017A (ja) * 1995-11-17 2000-01-11 ウォルフガンク−エム フランツ 遺伝子治療核酸構造体、その製造と心臓疾患治療へのその利用
US6120520A (en) 1997-05-27 2000-09-19 Angiotrax, Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
US6051008A (en) 1996-12-02 2000-04-18 Angiotrax, Inc. Apparatus having stabilization members for percutaneously performing surgery and methods of use
US6102926A (en) 1996-12-02 2000-08-15 Angiotrax, Inc. Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use
EP1064356A2 (de) * 1998-03-23 2001-01-03 ZymoGenetics, Inc. Herz-derivierte stammzellen
US20030113301A1 (en) * 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
DE10014690A1 (de) * 2000-03-24 2001-10-18 Franz Wolfgang M Verfahren zur Isolierung in vito differenzierter Körperzellen
AU2001273421A1 (en) 2000-07-13 2002-01-30 Bioheart, Inc. Deployment system for myocardial cellular material
AU2001284695A1 (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20110091428A1 (en) * 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US7862810B2 (en) * 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
DE10136702B4 (de) 2000-12-27 2004-04-22 Axiogenesis Ag System zur zell- und entwicklungsspezifischen Selektion differenzierender embryonaler Stammzellen, adulter Stammzellen und embryonaler Keimbahnzellen
EP1348019B9 (de) * 2000-12-27 2012-04-18 Axiogenesis Ag System zur zell-und entwicklungsspezifischen selektion differenzierender embryonaler stammzellen; adulter stammzellen und embryonaler keinbahnzellen
EP1271145A1 (de) * 2001-06-25 2003-01-02 Cardion AG Verfahren und Zellpopulationen fur die Identifizierung und die Validierung von Zielgenen und zum Screening von Wirkstoffen
JP2004535199A (ja) * 2001-07-12 2004-11-25 ジェロン コーポレイション ヒト多能性幹細胞から産生される心筋細胞系譜の細胞
US7732199B2 (en) 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
AU2002331365B2 (en) * 2001-08-02 2007-11-15 Altana Pharma Ag Novel recombinant gene expression method by stop codon suppression
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
US6893431B2 (en) 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
US7364567B2 (en) * 2002-06-10 2008-04-29 Abbott Cardiovascular Systems Inc. Systems and methods for detecting tissue contact and needle penetration depth
US8574195B2 (en) * 2002-06-10 2013-11-05 Advanced Cardiovascular Systems, Inc. Systems and methods for detecting tissue contact and needle penetration depth using static fluid pressure measurements
WO2004011603A2 (en) * 2002-07-26 2004-02-05 Wisconsin Alumni Research Foundation Functional cardiomyocytes from human embryonic stem cells
US20040191225A1 (en) * 2002-08-06 2004-09-30 Dinsmore Jonathan H. Injection system
JP2004246317A (ja) * 2002-12-20 2004-09-02 Hitachi Ltd 冷陰極型フラットパネルディスプレイ
WO2004113515A2 (en) * 2003-06-20 2004-12-29 Axiogenesis Ag Tissue modeling in embryonic stem (es) cell system
US8426200B2 (en) * 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
US8308708B2 (en) 2003-07-15 2012-11-13 Abbott Cardiovascular Systems Inc. Deployment system for myocardial cellular material
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US20050214938A1 (en) * 2004-03-26 2005-09-29 Gold Joseph D Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function
CA2560334A1 (en) 2004-04-07 2005-10-20 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
WO2005108598A1 (en) 2004-05-11 2005-11-17 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
CA2611809C (en) 2005-06-22 2018-06-19 Geron Corporation Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
WO2008063675A2 (en) * 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
SG188098A1 (en) 2008-01-30 2013-03-28 Geron Corp Synthetic surfaces for culturing stem cell derived cardiomyocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012233A1 (en) * 1991-12-16 1993-06-24 The University Of North Carolina At Chapel Hill Mammalian cell-based dna libraries

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012233A1 (en) * 1991-12-16 1993-06-24 The University Of North Carolina At Chapel Hill Mammalian cell-based dna libraries

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DE WET J.R. ET AL.: "Firefly luciferase gene: structure and expression in mammalian cells", MOLECULAR AND CELLULAR BIOLOGY, vol. 7, no. 2, 1987, WASHINGTON US, pages 725 - 737, XP002001051 *
ENGELMANN GL ET AL: "Formation of fetal rat cardiac cell clones by retroviral transformation: retention of select myocyte characteristics.", J MOL CELL CARDIOL, FEB 1993, 25 (2) P197-213, ENGLAND, XP000568169 *
HUNTER J. ET AL.: "Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 39, 1995, MD US, pages 23173 - 23178, XP002001049 *
LEE K.J. ET AL.: "Myosing light chain-2 luciferase transgenic mice reveal distindt regulatory programs for cardiac and skeletal muscle-specific expression of a single contractile protein gene", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 22, 1992, MD US, pages 15875 - 15885, XP002001050 *
WOBUS A M ET AL: "Retinoic acid induces expression of the ventricular 2.1 kb myosin-light-chain-2 promoter during in vitro cardiogenesis of embryonic stem cells", CIRCULATION, 92 (8 SUPPL.). 1995. I114., XP002001047 *

Also Published As

Publication number Publication date
US5928943A (en) 1999-07-27
EP0787182A2 (de) 1997-08-06
DE4441327C1 (de) 1995-11-09
WO1996016163A2 (de) 1996-05-30

Similar Documents

Publication Publication Date Title
WO1996016163A3 (de) Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung
Ketner et al. Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone.
Stratford-Perricaudet et al. Widespread long-term gene transfer to mouse skeletal muscles and heart.
KR100377889B1 (ko) 핵산을함유하는조성물,제조및용도
EP0198328B1 (de) DNS-Vakzine
CA2183151A1 (fr) Systeme hote-vecteur utilisable en therapie genique
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
DE60116513T2 (de) Adenovirenvektoren zur transduktion der chondrozyten
Lipps et al. Chromosome-based vectors for gene therapy
CA2184345A1 (en) Coordinate in vivo gene expression
WO1999009193A1 (de) Hüllprotein-modifizierter baculovirus-vektor für die gentherapie
CA2163427A1 (en) Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
EP0689604A1 (de) Verfahren zur herstellung von krebsvakzinen
Edwards et al. An Escherichia coli tyrosine transfer RNA is a leucine-specific transfer RNA in the yeast Saccharomyces cerevisiae.
DE19639103A1 (de) Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
DE4421079C1 (de) Chimäres Peptid-Nukleinsäure-Fragment, Verfahren zu seiner Herstellung und die Verwendung des Fragments zur zielgerichteten Nukleinsäureeinbringung in Zellorganellen und Zellen
DE60117053T2 (de) Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten
EP1544305A1 (de) Adapter zum Ankoppeln einer an einer Zelloberfläche anzukoppelnden Substanz
CA2110266A1 (en) Enhancement of Expression by Gene Targeting in Endogenous Retrovirus-Like Sequences
Green et al. Effect of mic gene structure on repressor activity in the OmpA system
DE69434019T2 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung
RU2240348C2 (ru) Последовательность нуклеиновой кислоты, которая обеспечивает поддержание эписомальной репликации в клетке млекопитающего, и вектор ее включающий
Doignon et al. The complete sequence of a 6794 bp segment located on the right arm of chromosome II of Saccharomyces cerevisiae. Finding of a putative dUTPase in a yeast
IL300395A (en) A platform vector for modular and easy introduction of transgenes into alphaherpessuirinae
Bulboaca et al. Telomeric sequences from human herpesvirus 6 do not mediate nuclear retention of episomal DNA in human cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995940117

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995940117

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08849706

Country of ref document: US